----

----

|  x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---------|-----------------------------------------------------------------------------------------|
|    |                                                                                    |
|    | For the quarter ended April 30, 2011                                                    |
|    |                                                                                    |
|    | OR                                                                                      |
|    |                                                                                    |
|  o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 |

|   | Large accelerated filer |  ̈ |   | Accelerated filer         |  ̈ |
|--------|-------------------------|--------|--------|---------------------------|--------|
|   |                    |   |   |                      |   |
|   | Non-accelerated filer   |  ̈ |   | Smaller reporting company | x      |

----

----

----

|                                                                                                                                                                                                                                                                                                                                                            |            |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|--------|
| Condensed Consolidated Balance Sheets as of April 30, 2011 (unaudited) and October 31, 2010                                                                                                                                                                                                                                                                |  F-1       |   |
|                                                                                                                                                                                                                                                                                                                                                            |            |   |
| Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended April 30, 2011 and 2010 (unaudited) and  the period from inception September 25, 2002 through April 30, 2011 (unaudited)                     |  F-2       |   |
|                                                                                                                                                                                                                                                                                                                                                            |            |   |
| Condensed Consolidated Statements of Stockholders’ Deficit for the period from inception September 25, 2002 through April 30, 2011 (unaudited)                                                                                                                                                                                                  |  F-3       |   |
|                                                                                                                                                                                                                                                                                                                                                            |            |   |
| Condensed Consolidated Statements of Cash Flows for the six months ended April 30, 2011 and 2010 (unaudited) and the period from inception September 25, 2002 throughApril 30, 2011 (unaudited)                                                                                                                                                  |  F-4       |   |
|                                                                                                                                                                                                                                                                                                                                                            |            |   |
|                                                                                                                                                                                                                                                                                                                                                            |            |   |
| Notes to Condensed Consolidated Financial Statements (unaudited)                                                                                                                                                                                                                                                                                           |  F-5 - F-7 |   |

----

| ADVANCED BIOMEDICAL TECHNOLOGIES, INC. ("ABMT")                                                  |   |
|--------------------------------------------------------------------------------------------------|--------|
| AND SUBSIDIARIES                                                                                 |   |
| (A DEVELOPMENT STAGE COMPANY)                                                                    |   |
| CONDENSED CONSOLIDATED BALANCE SHEETS                                                            |   |
|                                                                                             |   |   |   |   |   |   |
|                                                                                             |   |   |   |   |   |   |
| ASSETS                                                                                           |   |
|                                                                                             |   | April 30, |   |   | October 31, |   |
|                                                                                             |   | 2011 |   |   | 2010 |   |
|                                                                                             |   | Unaudited |   |   |   |   |
|                                                                                             |   |   |   |   |   |   |
| CURRENT ASSETS                                                                                   |   |   |   |   |   |   |
| Cash and cash equivalents                                                                        |   | $ | 33,695 |   |   | $ | 38,614 |   |
| Government grants receivable                                                                     |   |   | 244,479 |   |   |   | - |   |
| Other receivables and prepaid expenses                                                           |   |   | 13,556 |   |   |   | 12,623 |   |
| Total Current Assets                                                                             |   |   | 291,730 |   |   |   | 51,237 |   |
|                                                                                             |   |   |   |   |   |   |   |   |
| PROPERTY AND EQUIPMENT, NET                                                                      |   |   | 48,104 |   |   |   | 49,461 |   |
| TOTAL ASSETS                                                                                     |   | $ | 339,834 |   |   | $ | 100,698 |   |
|                                                                                             |   |   |   |   |   |   |   |   |
| LIABILITIES AND STOCKHOLDERS' DEFICIT                                                            |   |
|                                                                                             |   |   |   |   |   |   |   |   |
| CURRENT LIABILITIES                                                                              |   |   |   |   |   |   |   |   |
| Other payables and accrued expenses                                                              |   | $ | 24,704 |   |   | $ | 25,711 |   |
| Due to a stockholder                                                                             |   |   | 113,025 |   |   |   | 217,951 |   |
| Due to directors                                                                                 |   |   | 147,815 |   |   |   | 158,941 |   |
| Due to a related company                                                                         |   |   | 411,402 |   |   |   | 400,192 |   |
| Due to related parties                                                                           |   |   | 864,933 |   |   |   | 788,400 |   |
| Total Current Liabilities                                                                        |   |   | 1,561,879 |   |   |   | 1,591,195 |   |
|                                                                                             |   |   |   |   |   |   |   |   |
|                                                                                             |   |   |   |   |   |   |   |   |
| COMMITMENTS AND CONTINGENCIES                                                                    |   |   | - |   |   |   | - |   |
|                                                                                             |   |   |   |   |   |   |   |   |
| DEFICIT                                                                                          |   |   |   |   |   |   |   |   |
| ABMT Stockholders' Deficit                                                                       |   |   |   |   |   |   |   |   |
| Common stock, $0.00001 par value, 100,000,000 shares                                             |   |   |   |   |   |   |   |   |
| authorized,  56,374,850 and 56,144,850 shares                                          |   |   |   |   |   |   |   |   |
|     issued and outstanding as of April 30, 2011 and October 31, 2010              |   |   | 564 |   |   |   | 562 |   |
| Common stock, 230,000 shares to be issued                                                        |   |   | - |   |   |   | 2 |   |
| Stock subscription receivable                                                                    |   |   | - |   |   |   | (230,000 | ) |
| Additional paid-in capital                                                                       |   |   | 1,508,172 |   |   |   | 1,494,551 |   |
| Deferred stock compensation                                                                      |   |   | (80,208 | ) |   |   | (206,459 | ) |
| Accumulated deficit during development stage                                                     |   |   | (2,502,662 | ) |   |   | (2,436,044 | ) |
| Accumulated other comprehensive loss                                                             |   |   | (147,911 | ) |   |   | (113,109 | ) |
| Total ABMT Stockholders' Deficit                                                                 |   |   | (1,222,045 | ) |   |   | (1,490,497 | ) |
|                                                                                             |   |   |   |   |   |   |   |   |
| Noncontrolling interests                                                                         |   |   | - |   |   |   | - |   |
| Total Deficit                                                                                    |   |   | (1,222,045 | ) |   |   | (1,490,497 | ) |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT                                                      |   | $ | 339,834 |   |   | $ | 100,698 |   |
|                                                                                             |   |   |   |   |   |   |   |   |
|                                                                                             |   |   |   |   |   |   |   |   |
| The accompanying notes are an integral part of these condensed consolidated financial statements |   |
|                                                                                             |   |   |   |   |   |   |   |   |
|                                                                                             |

----

| ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES                                          |
|--------------------------------------------------------------------------------------------------|
| (A DEVELOPMENT STAGE COMPANY)                                                                    |
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)                  |   |
|                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                             |   |  (UNAUDITED) |   |   |   |   |   |   |   |   |   |   |
|                                                                                             |   | Three months ended |   |   | Six months ended |   |   | September 25, 2002 |   |
|                                                                                             |   | April 30, |   |   | April 30, |   |   | (Inception) through |   |
|                                                                                             |   | 2011 |   |   | 2010 |   |   | 2011 |   |   | 2010 |   |   | April 30, 2011 |   |
|                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| OPERATING EXPENSES                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| General and administrative expenses                                                              |   | $ | 139,358 |   |   | $ | 112,600 |   |   | $ | 265,211 |   |   | $ | 257,200 |   |   | $ | 2,247,580 |   |
| Depreciation                                                                                     |   |   | 1,285 |   |   |   | 7,387 |   |   |   | 2,593 |   |   |   | 14,839 |   |   |   | 263,963 |   |
| Research and development (Net of                                                                 |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|   government grant)                                                                    |   |   | - |   |   |   | - |   |   |   | 30 |   |   |   | 1,840 |   |   |   | 119,063 |   |
| Total Operating Expenses                                                                         |   |   | 140,643 |   |   |   | 119,987 |   |   |   | 267,834 |   |   |   | 273,879 |   |   |   | 2,630,606 |   |
|                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| LOSS FROM OPERATIONS                                                                             |   |   | (140,643 | ) |   |   | (119,987 | ) |   |   | (267,834 | ) |   |   | (273,879 | ) |   |   | (2,630,606 | ) |
|                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| OTHER INCOME (EXPENSES)                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Government grants                                                                                |   |   | 244,479 |   |   |   | - |   |   |   | 244,479 |   |   |   | - |   |   |   | 244,479 |   |
| Interest income                                                                                  |   |   | 12 |   |   |   | 23 |   |   |   | 36 |   |   |   | 36 |   |   |   | 1,637 |   |
| Interest paid to a stockholder                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|   and related parties                                                                  |   |   | (14,612 | ) |   |   | (15,698 | ) |   |   | (29,438 | ) |   |   | (28,529 | ) |   |   | (129,833 | ) |
| Imputed interest                                                                                 |   |   | (6,781 | ) |   |   | (6,673 | ) |   |   | (13,621 | ) |   |   | (14,061 | ) |   |   | (190,705 | ) |
| Other income (expenses)                                                                          |   |   | (519 | ) |   |   | (2,494 | ) |   |   | (240 | ) |   |   | (2,787 | ) |   |   | (14,839 | ) |
| Total Other Income (Expenses), net                                                               |   |   | 222,579 |   |   |   | (24,842 | ) |   |   | 201,216 |   |   |   | (45,341 | ) |   |   | (89,261 | ) |
|                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| INCOME (LOSS) FROM OPERATIONS BEFORE TAXES                                                       |   |   | 81,936 |   |   |   | (144,829 | ) |   |   | (66,618 | ) |   |   | (319,220 | ) |   |   | (2,719,867 | ) |
| Income tax expense                                                                               |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
| NET INCOME (LOSS)                                                                                |   |   | 81,936 |   |   |   | (144,829 | ) |   |   | (66,618 | ) |   |   | (319,220 | ) |   |   | (2,719,867 | ) |
| Net loss attributable to noncontrolling interests                                                |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 217,205 |   |
| NET INCOME (LOSS) ATTRIBUTABLE TO ABMT                                                           |   |   |   |   |   |   |   |   |   |   |   |   |
| COMMON STOCKHOLDERS                                                                              |   |   | 81,936 |   |   |   | (144,829 | ) |   |   | (66,618 | ) |   |   | (319,220 | ) |   |   | (2,502,662 | ) |
|                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| OTHER COMPREHENSIVE LOSS                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Total other comprehensive loss                                                                   |   |   | (17,946 | ) |   |   | (158 | ) |   |   | (34,802 | ) |   |   | (114 | ) |   |   | (147,911 | ) |
| Add: foreign currency translation loss                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| attributable to noncontrolling interest                                                          |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
| Foreign currency translation loss                                                                |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| attributable to ABMT common stockholders                                                         |   |   | (17,946 | ) |   |   | (158 | ) |   |   | (34,802 | ) |   |   | (114 | ) |   |   | (147,911 | ) |
| COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE                                                         |   |   |   |   |   |   |   |   |   |
| TO ABMT COMMON STOCKHOLDERS                                                                      |   | $ | 63,990 |   |   | $ | (144,987 | ) |   | $ | (101,420 | ) |   | $ | (319,334 | ) |   | $ | (2,650,573 | ) |
|                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net income (loss) per share-basic and diluted                                                    |   | $ | 0.00 |   |   | $ | (0.00 | ) |   | $ | (0.00 | ) |   | $ | (0.01 | ) |   |   |   |   |
|                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Weighted average number of shares                                                                |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| outstanding during the period                                                                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| - basic and diluted                                                                              |   |   | 56,374,850 |   |   |   | 55,732,159 |   |   |   | 56,374,850 |   |   |   | 55,775,130 |   |   |   |   |   |
|                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| The accompanying notes are an integral part of these condensed consolidated financial statements |   |
|                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                             |
| F-2                                                                                              |

----

| ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES                                                |   |
|--------------------------------------------------------------------------------------------------------|--------|
| (A DEVELOPMENT STAGE COMPANY)                                                                          |   |
| CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT (UNAUDITED)                           |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | Accumulated |   |   | Accumulated |   |   |   |   |   |
|                                                                                                   |   | Common Stock |   |   | Shares to be issued |   |   | Stock |   |   | Additional |   |   | Deferred |   |   | deficit during |   |   | other |   |   |   |   |   |   |   |
|                                                                                                   |   | Number |   |   |   |   |   |   |   | Number of |   |   | subscriptions |   |   | Paid-in |   |   | Stock |   |   | development |   |   | comprehensive |   |   | Noncontrolling |   |
|                                                                                                   |   | of Shares |   |   | Amount |   |   | Shares |   |   | Amount |   |   | receivable |   |   | capital |   |   | Compensation |   |   | stage |   |   | loss |   |   | interests |   |   | Total |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued to founders for cash                                                                      |   |   | 50,510,000 |   |   | $ | 505 |   |   |   | - |   |   | $ | - |   |   | $ | - |   |   | $ | 275,002 |   |   | $ | - |   |   | $ | - |   |   | $ | - |   |   | $ | 217,205 |   |   | $ | 492,712 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the period                                                                                |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (40,343 | ) |   |   | - |   |   |   | (17,290 | ) |   |   | (57,633 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                                      |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (225 | ) |   |   | 10 |   |   |   | (215 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                                     |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (57,848 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2003                                                                           |   |   | 50,510,000 |   |   |   | 505 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 275,002 |   |   |   | - |   |   |   | (40,343 | ) |   |   | (225 | ) |   |   | 199,925 |   |   |   | 434,864 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                                                  |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (65,960 | ) |   |   | - |   |   |   | (28,269 | ) |   |   | (94,229 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                                      |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (357 | ) |   |   | 2 |   |   |   | (355 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                                     |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (94,584 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2004                                                                           |   |   | 50,510,000 |   |   |   | 505 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 275,002 |   |   |   | - |   |   |   | (106,303 | ) |   |   | (582 | ) |   |   | 171,658 |   |   |   | 340,280 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholderand related company                                     |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 23,103 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 23,103 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                                                  |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (357,863 | ) |   |   | - |   |   |   | (153,370 | ) |   |   | (511,233 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                                      |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (12,290 | ) |   |   | 2,064 |   |   |   | (10,226 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                                     |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (521,459 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2005                                                                           |   |   | 50,510,000 |   |   |   | 505 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 298,105 |   |   |   | - |   |   |   | (464,166 | ) |   |   | (12,872 | ) |   |   | 20,352 |   |   |   | (158,076 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholderand related company                                     |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 27,184 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 27,184 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                                                  |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (172,738 | ) |   |   | - |   |   |   | (18,276 | ) |   |   | (191,014 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                                      |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (6,084 | ) |   |   | (2,076 | ) |   |   | (8,160 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                                     |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (199,174 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2006                                                                           |   |   | 50,510,000 |   |   |   | 505 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 325,289 |   |   |   | - |   |   |   | (636,904 | ) |   |   | (18,956 | ) |   |   | - |   |   |   | (330,066 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder, related company and related party                     |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 39,021 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 39,021 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                                                  |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (196,871 | ) |   |   | - |   |   |   | - |   |   |   | (196,871 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                                      |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (27,401 | ) |   |   | - |   |   |   | (27,401 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                                     |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (224,272 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2007                                                                           |   |   | 50,510,000 |   |   |   | 505 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 364,310 |   |   |   | - |   |   |   | (833,775 | ) |   |   | (46,357 | ) |   |   | - |   |   |   | (515,317 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholderand related company                                |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 27,764 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 27,764 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the period                                                                                |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (227,038 | ) |   |   | - |   |   |   | - |   |   |   | (227,038 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                                      |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (35,833 | ) |   |   | - |   |   |   | (35,833 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                                     |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (262,871 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at October 31,2008                                                                             |   |   | 50,510,000 |   |   |   | 505 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 392,074 |   |   |   | - |   |   |   | (1,060,813 | ) |   |   | (82,190 | ) |   |   | - |   |   |   | (750,424 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Recapitalization                                                                                       |   |   | 5,104,000 |   |   |   | 51 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (51 | ) |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($3.05 per share)                                                            |   |   | 100,000 |   |   |   | 1 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 304,999 |   |   |   | (292,292 | ) |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 12,708 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1.15 per share)                                           |   |   | 5,000 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 5,750 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 5,750 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1.15 per share)                                           |   |   | 2,000 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 2,300 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 2,300 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Contributed capital                                                                                    |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 26,950 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 26,950 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Distributed to the stockholders                                                                        |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (31,409 | ) |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (31,409 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed Interest on advances from a stockholderand related company                                     |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 31,656 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 31,656 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                                                  |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (558,432 | ) |   |   | - |   |   |   | - |   |   |   | (558,432 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                                      |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (1,856 | ) |   |   | - |   |   |   | (1,856 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                                     |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (560,288 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at October 31, 2009                                                                            |   |   | 55,721,000 |   |   |   | 557 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 732,269 |   |   |   | (292,292 | ) |   |   | (1,619,245 | ) |   |   | (84,046 | ) |   |   | - |   |   |   | (1,262,757 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1.5 per share)                                            |   |   | 6,667 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 10,000 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 10,000 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1.5 per share)                                            |   |   | 16,667 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 25,000 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 25,000 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1.5 per share)                                            |   |   | 136,833 |   |   |   | 2 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 205,248 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 205,250 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock to be issued for cash in private placement ($1.0 per share)                                      |   |   | - |   |   |   | - |   |   |   | 230,000 |   |   |   | 2 |   |   |   | (230,000 | ) |   |   | 229,998 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($1 per share)                                                               |   |   | 100,000 |   |   |   | 1 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 99,999 |   |   |   | (100,000 | ) |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($1 per share)                                                               |   |   | 13,683 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 13,683 |   |   |   | (13,683 | ) |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($1 per share)                                                               |   |   | 150,000 |   |   |   | 2 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 149,998 |   |   |   | (150,000 | ) |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Amortisation for stock issued for services                                                             |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 349,516 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 349,516 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholderand related company                                |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 28,356 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 28,356 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                                                  |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (816,799 | ) |   |   | - |   |   |   | - |   |   |   | (816,799 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                                      |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (29,063 | ) |   |   | - |   |   |   | (29,063 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                                     |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (845,862 | ) |
| Balance at October 31, 2010                                                                            |   |   | 56,144,850 |   |   |   | 562 |   |   |   | 230,000 |   |   |   | 2 |   |   |   | (230,000 | ) |   |   | 1,494,551 |   |   |   | (206,459 | ) |   |   | (2,436,044 | ) |   |   | (113,109 | ) |   |   | - |   |   |   | (1,490,497 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1 per share)                                              |   |   | 230,000 |   |   |   | 2 |   |   |   | (230,000 | ) |   |   | (2 | ) |   |   | 230,000 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 230,000 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder and related company                               |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 13,621 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 13,621 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Amortisation for stock issued for services                                                             |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 126,251 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 126,251 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the period                                                                                |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (66,618 | ) |   |   | - |   |   |   | - |   |   |   | (66,618 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                                      |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (34,802 | ) |   |   | - |   |   |   | (34,802 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                                     |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (101,420 | ) |
| Balance at April 30, 2011                                                                              |   |   | 56,374,850 |   |   | $ | 564 |   |   |   | - |   |   | $ | - |   |   | $ | - |   |   | $ | 1,508,172 |   |   | $ | (80,208 | ) |   | $ | (2,502,662 | ) |   | $ | (147,911 | ) |   | $ | - |   |   | $ | (1,222,045 | ) |
|                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                   |
|  The accompanying notes are an integral part of these condensed consolidated financial statements |
|                                                                                                   |

----

| ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES |
|---------------------------------------------------------|
| (A DEVELOPMENT STAGE COMPANY)                           |
|  CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS   |
|  (UNAUDITED)                                       |
|                                                    |

|                                                                                             |   | Six months ended |     |   | September 25, 2002  |   |
|--------------------------------------------------------------------------------------------------|--------|------------------|----------|--------|---------------------|--------|
|                                                                                             |   | April 30,        |     |   | (inception) through |   |
|                                                                                             |   | 2011             |     |   | 2010                |   |   | April 30, 2011 |   |
|                                                                                             |   |             |     |   |                |   |   |   |   |
| CASH FLOWS FROM OPERATING ACTIVITIES                                                             |   |             |     |   |                |   |   |   |   |
| Net loss                                                                                         |   | $                | (66,618  | )      |                | $      | (319,220 | ) |   | $ | (2,502,662 | ) |
| Adjustments to reconcile net loss to cash                                                        |   |             |     |   |                |   |   |   |   |   |   |   |
| used in operating activities:                                                                    |   |             |     |   |                |   |   |   |   |   |   |   |
|  Depreciation                                                                               |   |             | 2,593    |   |                |   | 14,839 |   |   |   | 263,963 |   |
| Loss on disposal of fixed assets                                                                 |   |             | -        |   |                |   | - |   |   |   | 5,328 |   |
| Stock issued for services                                                                        |   |             | 126,251  |   |                |   | 76,250 |   |   |   | 488,475 |   |
| Noncontrolling interests                                                                         |   |             | -        |   |                |   | - |   |   |   | (217,205 | ) |
|  Imputed interest                                                                      |   |             | 13,621   |   |                |   | 14,061 |   |   |   | 190,705 |   |
| Changes in operating assets and liabilities                                                      |   |             |     |   |                |   |   |   |   |   |   |   |
|    (Increase) decrease in:                                                             |   |             |     |   |                |   |   |   |   |   |   |   |
| Government grants receivable                                                                     |   |             | (244,479 | )      |                |   | - |   |   |   | (244,479 | ) |
| Other receivables and prepaid expenses                                                           |   |             | (571     | )      |                |   | (2,252 | ) |   |   | (13,556 | ) |
|    Increase (decrease) in:                                                             |   |             |     |   |                |   |   |   |   |   |   |   |
| Other payables and accrued expenses                                                              |   |             | (1,120   | )      |                |   | (15,232 | ) |   |   | 24,704 |   |
| Net cash used in operating activities                                                            |   |             | (170,323 | )      |                |   | (231,554 | ) |   |   | (2,004,727 | ) |
|                                                                                             |   |             |     |   |                |   |   |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES                                                             |   |             |     |   |                |   |   |   |   |   |   |   |
| Purchase of property and equipment                                                               |   |             | -        |   |                |   | (4,389 | ) |   |   | (317,395 | ) |
| Net cash used in investing activities                                                            |   |             | -        |   |                |   | (4,389 | ) |   |   | (317,395 | ) |
|                                                                                             |   |             |     |   |                |   |   |   |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES                                                             |   |             |     |   |                |   |   |   |   |   |   |   |
| Stock issued to founders                                                                         |   |             | -        |   |                |   | - |   |   |   | 505 |   |
| Proceeds from issuance of shares                                                                 |   |             | 230,000  |   |                |   | 240,250 |   |   |   | 478,300 |   |
| Contribution by stockholders                                                                     |   |             | -        |   |                |   | - |   |   |   | 519,157 |   |
| Distributed to stockholders                                                                      |   |             | -        |   |                |   | - |   |   |   | (31,409 | ) |
|    Due to a stockholder                                                                |   |             | (104,855 | )      |                |   | (131,411 | ) |   |   | 113,025 |   |
|    Due to directors                                                                    |   |             | (15,043  | )      |                |   | (47,727 | ) |   |   | 147,815 |   |
| Due to a related company                                                                         |   |             | -        |   |                |   | - |   |   |   | 411,402 |   |
|    Due to related parties                                                              |   |             | 53,769   |   |                |   | 213,907 |   |   |   | 864,933 |   |
| Net cash provided by financing activities                                                        |   |             | 163,871  |   |                |   | 275,019 |   |   |   | 2,503,728 |   |
|                                                                                             |   |             |     |   |                |   |   |   |   |   |   |   |
| EFFECT ON EXCHANGE RATES ON CASH                                                                 |   |             | 1,533    |   |                |   | (8 | ) |   |   | (147,911 | ) |
|                                                                                             |   |             |     |   |                |   |   |   |   |   |   |   |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS                                             |   |             | (4,919   | )      |                |   | 39,068 |   |   |   | 33,695 |   |
|                                                                                             |   |             |     |   |                |   |   |   |   |   |   |   |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                                                 |   |             | 38,614   |   |                |   | 10,606 |   |   |   | - |   |
|                                                                                             |   |             |     |   |                |   |   |   |   |   |   |   |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD                                                       |   | $                | 33,695   |   |                | $      | 49,674 |   |   | $ | 33,695 |   |
|                                                                                             |   |             |     |   |                |   |   |   |   |   |   |   |
|                                                                                             |   |             |     |   |                |   |   |   |   |   |   |   |
|                                                                                             |   |
|                                                                                             |   |
| The accompanying notes are an integral part of these condensed consolidated financial statements |   |

----

----

|   | (1) | The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

| 1.   | A notably reduced need for a secondary surgery to remove implant due to post-operative complications, therefore avoiding unnecessary risk and expense on all patient care; |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.   | Enhancing the performance of the materials by manufacturing them to be easily fitted to each patient, forming an exact fit; |
|----------------|-----------------------------------------------------------------------------------------------------------------------------|

| 3.   | Improving the biological activity of materials. Clinical trial results have shown that as PA implants degrade, they promote a progressive shift of load to the new bone creating micro-motion and thereby avoiding bone atrophy due to 'stress shielding'; |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.   | Reducing the chance of post-operative infection; |
|----------------|--------------------------------------------------|

| 5.   | Effectively controlling the degeneration speed, so that there will be no complications in treating repeat injuries; |
|----------------|---------------------------------------------------------------------------------------------------------------------|

| 6.   | Ease of post-operative care i.e. no distortion during x-ray imaging; |
|----------------|----------------------------------------------------------------------|

| 7.   | Simple and cost-effective to manufacture. |
|----------------|-------------------------------------------|

----

----

| Estimate current production lines in full capacity |                              |   |                   |
|----------------------------------------------------|-----------------------------------|--------|--------------------------|
|                                             | Output Quantity (Max.)            |   | Price at ex-factory (U$) |   |   | Total Turnover (U$) |
| PA Screw                                           |    100,000 (piece) |   |                     | 180 |   |   |   | 18,000,000 |
| PA Binding Wire                                    |    240,000 (pack)  |   |                     |   50 |   |   |   | 12,000,000 |
|                                             |                            |   |  Total:           |   |   |   | 30,000,000 |

----

----

| Statistic and Census report by Ministry of Health of People's Republic of China.            |
|---------------------------------------------------------------------------------------------|
| (Year 2009)                                                                                 |
|                                                                                      |   |   |   |   | Total | Total |
|                                                                                      | Total | Government | Society | Private | Non-Profit | Profit |
| Hospitals                                                                                   | 19712 | 9777 | 6048 | 3887 | 15650 | 4038 |
|    General Hospital                                                          | 13119 | 5830 | 5060 | 2229 | 10856 | 2245 |
|    TCM Hospital                                                              | 2688 | 2244 | 158 | 286 | 2403 | 285 |
|    TCM-WM Hospital                                                           | 236 | 96 | 48 | 92 | 139 | 97 |
|    Minority Hospital                                                         | 191 | 170 | 8 | 13 | 175 | 16 |
|    Specialist Hospital                                                       | 3437 | 1422 | 763 | 1252 | 2048 | 1383 |
|    Nursing Hospital                                                          | 41 | 15 | 11 | 15 | 29 | 12 |
|                                                                               |
| TCM Hospital:  Traditional Chinese Medicine Hospital                       |
| WM Hospital:  Western Medicine Hospital                                    |
| Minority Hospital:  The hospitals locate in Autonomous Region (Province) in China |

----

----

|                                             |   | Three months ended |    |   | Six months ended |   |    | September 25, 2002  |   |
|--------------------------------------------------|--------|--------------------|---------|--------|------------------|--------|---------|---------------------|--------|
|                                             |   | April 30,          |    |   | April 30,        |   |    | (Inception) through |   |
|                                             |   | 2011               |    |   | 2010             |   |    | 2011                |   |   | 2010 |   |   | April 30, 2011 |   |
|                                             |   |               |    |   |             |   |    |                |   |   |   |   |   |   |   |
| Interest paid to directors and a related company |   | $                  | (6,781) |   |             |   | (6,673) |                |   |   | (13,621) |   |   |   | (14,061) |   |   |   | (190,705) |   |

----

|  1. |   | Property and equipment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|----------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|     |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|     |   | Property and equipment are stated at cost, less accumulated depreciation.  Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.                                                                                                                                                                                                                                                                                                                                                                                                        |
|     |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|     |   | Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives.  The estimated useful lives of the assets are 5 years.                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|     |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|  2. |   | Long-lived assets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|     |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|     |   | In accordance with FASB Codification Topic 360 (ASC Topic 360), “Accounting for the impairment or disposal of Long-Lived Assets", long-lived assets and certain identifiable intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, the recoverability test is performed using undiscounted net cash flows related to the long- lived assets. The Company reviews long-lived assets to determine that carrying values are not impaired. |

----

|     |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |   |
|----------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| 3.       |   | Fair value of financial instruments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|     |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|     |   | FASB Codification Topic 825(ASC Topic 825), "Disclosure About Fair Value of Financial Instruments," requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses, due from related parties, other payables and accrued liabilities and due to related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.                                                                                                                                                                       |
|     |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 4.  |   | Government  grants                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|     |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|     |   | Government grants are recognized when there is reasonable assurance that the Company complies with any conditions attached to them and the grants will be received.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|     |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 5.  |   | Income taxes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|     |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|     |   | The Company accounts for income taxes under the FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period included the enactment date. |
|     |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 6.  |   | Research and Development                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|     |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|     |   | Research and development costs related to both present and future products are expensed as incurred.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|     |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 7.  |   | Foreign currency translation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|     |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|     |   | The financial statements of the Company’s subsidiary denominated in currencies other than US dollars are translated into US dollars using the closing rate method.  The balance sheet items are translated into US dollars using the exchange rates at the respective balance sheet dates.  The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year.  All exchange differences are recorded within equity.                                                                                                                                                                   |

----

----

----

31.1                                                    Section 302 Certification of Chief Executive Officer*

31.2                                                    Section 302 Certification of Chief Financial Officer *

32.1                                                    Section 906 Certification of Chief Executive Officer *

32.2                                                    Section 906 Certification of Chief Financial Officer *

| June 20, 2011 |  By: |                                          |
|---------------|-----------|-----------------------------------------------|
|          |      |   ADVANCED BIOMEDICAL TECHNOLOGIES, INC. |
|          |      |                                          |   |
|          |      | By:                                           | /s/Chi Ming YU |
|          |      |                                          | Chi Ming YU, President and Director |
|          |      |                                          |   |
|          |      |                                          |   |
|          |      | By:                                           | /s/ Wang Hui |
|          |      |                                          | Wang Hui, Director and Chief Executive Officer |
|          |      |                                          |   |
|          |      |                                          |   |
|          |      | By:                                           | /s/ Kai GUI |
|          |      |                                          | Kai GUI, Director, Secretary and Chief Financial Officer |